In the last couple of days, stock markets have experienced big volatility on rising interest rates. However, the stocks below have 100% buy ratings from analysts and top analysts alike- giving you confidence that these stocks have the backing of analysts who consistently get it right. To find these ‘Strong Buy’ rated stocks, we turned to TipRanks’ innovative stock screener. Here you can see the exact filters we used:

This allowed us to pull up only stocks with very bullish Street sentiment. From the extracted stocks, we scanned for stocks with 1) only buy ratings and 2) big upside potential. As you can see below, the screener displays all the key stats including analyst consensus and price target, and you can click on the tickers for further info.

From the results, the following five stocks easily stood out from the crowd- let’s take a closer look now:

1. Equinix (NASDAQ:EQIX)

  • 10 buy ratings in last three months
  • 22% upside potential from current share price
  • Now is a good time to invest in the world’s largest IBX data center & colocation provider according to top UBS analyst John Hodulik. He upgraded EQIX from hold to buy on January 29, while ramping up his price target $30 to $510 (16% upside). Hodulik says the stock’s risk/reward balance now looks more attractive given 1) recent stock weakness and 2) strong company fundamentals. He is now looking for revenue growth of 10.5% in 2018 to reflect an increasing global data center demand. Note that you can click on the screenshot below for further insights into the latest market activity on each stock.

    2. BioMarin (NASDAQ:BMRN)

  • 6 buy ratings in last three months
  • 34% upside potential from current share price
  • BioMarin develops and commercializes innovative treatments for rare genetic diseases. And top JP Morgan analyst Cory Kasmiov doesn’t mince his words when he says: “BMRN continues to be one of our top picks for 2018 with shares positioned to emerge from ~2 years of stagnation between a new product cycle & key pivotal readouts ahead.” Kasmiov reiterated his BMRN buy rating on January 24 with a bullish $129 price target (43% upside potential).

    Print Friendly, PDF & Email